Billing Codes

61563

Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent Applicable once per lifetime (R)

Schedule fee
$1300.00
was $1300.00
100% Benefit
85%: $1195.50
75%: $975.00
Category
Category 5 — Diagnostic Imaging
Group I4
Status
Unchanged
Full description

Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent Applicable once per lifetime (R)

Fee history

No recorded changes yet — history accumulates with each release.

Data sourced from Australian Government publications · Not an official government service